Docoh
Loading...

OCUL Ocular Therapeutix

News

Pro users get this 30m faster
10 Biggest Price Target Changes For Monday
18 Oct 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Barclays reduced the price target for The Walt Disney Company (NYSE: DIS) from $210 to $175. Disney shares fell 1.6% to $173.60 in pre-market trading.
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
18 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, General
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.
Raymond James Maintains Strong Buy on Ocular Therapeutix, Raises Price Target to $29
18 Oct 21
News, Price Target, Analyst Ratings
Raymond James analyst Dane Leone maintains Ocular Therapeutix (NASDAQ:OCUL) with a Strong Buy and raises the price target from $25 to $29.
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $18
12 Oct 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $17 to $18.
46 Biggest Movers From Yesterday
12 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
Why Are Ocular Therapeutix Shares Trading Higher Today?
11 Oct 21
Biotech, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Monday's Intraday Session
11 Oct 21
Intraday Update, Markets, Movers
Ocular Therapeutix Announces FDA Approval Of Supplemental New Drug Application For DEXTENZA 0.4 mg For Intracanalicular Use For Treatment Of Ocular Itching Associated With Allergic Conjunctivitis
11 Oct 21
News, FDA, Movers, Trading Ideas
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.S.
28 Stocks Moving In Monday's Mid-Day Session
11 Oct 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
Ocular Therapeutix Shares Move Higher; Traders Circulate Oct. 7 FDA Approval For Co's Dextenza
11 Oct 21
News, FDA, Movers, Trading Ideas
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208742
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
1 Oct 21
Biotech, News, Penny Stocks, Health Care, Small Cap, FDA, Top Stories, General
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned.
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $33
9 Sep 21
News, Price Target, Analyst Ratings
JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and raises the price target from $30 to $33.
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021
10 Aug 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
HC Wainwright & Co. Upgrades Ocular Therapeutix to Buy, Announces $17 Price Target
10 Aug 21
News, Upgrades, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Yi Chen upgrades Ocular Therapeutix (NASDAQ:OCUL) from Neutral to Buy and announces $17 price target.
Ocular Therapeutix Q2 EPS $(0.25) Misses $(0.21) Estimate, Sales $11.72M Beat $11.60M Estimate
9 Aug 21
Earnings, News
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 60.94 percent increase over losses of $(0.64) per share
Earnings Scheduled For August 9, 2021
9 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
8 Aug 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases
6 Aug 21
Biotech, News, Health Care, Contracts, Small Cap, General
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
6 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, IPOs, Top Stories
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5)
12 Health Care Stocks Moving In Thursday's After-Market Session
5 Aug 21
Movers
Gainers

Press releases

Pro users get this 30m faster
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
11 Oct 21
Press Releases
Approval represents the first primarily office-based indication for DEXTENZA Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of
Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts
13 Sep 21
Press Releases
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported in-market
Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
7 Sep 21
Press Releases
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it
Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference
10 Aug 21
Press Releases
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it
Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update
9 Aug 21
Press Releases
DEXTENZA® Recorded Net Quarterly Sales of $11.1 Million, Representing Quarterly Sequential Growth of Approximately 65% Initiated First Clinical Trial in the U.S. to Assess a Single OTX-TKI Implant Containing a
Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases
5 Aug 21
Press Releases
Ocular plans to Continue its Efforts to Explore Innovative Anti-VEGF Agents Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of
Thinking about buying stock in Acorda Therapeutics, Ocular Therapeutix, Ocugen, Aerpio Pharmaceuticals, or Anavex Life Sciences?
23 Jul 21
Opinion, Press Releases
NEW YORK, July 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACOR, OCUL, OCGN, ARPO, and AVXL.
Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
23 Jul 21
Press Releases
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple
Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million
22 Jul 21
Press Releases
Company Anticipates Record Quarter for In-Market DEXTENZA Sales Second Quarter 2021 Net Product Revenue Up Approximately 60% and In-Market Unit Volumes Up Approximately 50% Sequentially Over the First Quarter of